NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Roche Holding AG (OTCMKTS: RHHBY) concerning possible violations of federal securities laws.
On June 5, 2017, news reports stated that a new study showed that adding Roche Holding’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone. When this information was released, shares of Roche Holding fell in value.
If you suffered a loss in Roche Holding and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/RHHBY-Info-Request-Form-161.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.